Investor Relations

shareholder letter icon

Shareholder Letter

Shareholder Letter January 27, 2022

Recent Event

Alliance Global Partner's 2024 Healthcare Company Showcase

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. The Company’s lead drug candidate Berubicin is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM) an aggressive and incurable form of brain cancer.

Additionally the Company is advancing the development of its WP1244 drug technology which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents and is believed to be 500x more potent than daunorubicin in inhibiting tumor cell proliferation. Preclinical studies of WP1244 demonstrated high uptake in the brain with antitumor activity. CNS Pharmaceuticals is evaluating the use of WP1244 in the treatment of brain cancers pancreatic ovarian and lymphomas.

Investor Contact Information


CNS Pharmaceuticals, Inc.
2100 West Loop South
Suite 900
Houston, TX 77027

Investor Relations

Jenene Thomas
T: 833-475-8247

Transfer Agent

Continental Stock Transfer & Trust Company
1 State Street
30th Floor
New York, NY 10004
T: 800-509-5586